HLVX NASDAQ
HilleVax, Inc.
1W: +0.0%
1M: +1.5%
3M: +11.2%
1Y: +16.8%
3Y: -90.5%
$2.09
Last traded 2025-09-18 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$104.8M
52W Range1.34-2.17
Volume2,800,167
Avg Volume718,706
Beta0.77
Dividend—
Analyst Ratings
Company Info
CEORobert M. Hershberg
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2022-04-29
Websitexoma.com
75 State Street
Boston, MA 02109
US
Boston, MA 02109
US
617 213 5054
About HilleVax, Inc.
HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston, Massachusetts.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| TAKEDA PHARMACEUTICA | U-Tender | 6,724,000 | $1.95 | 2025-09-17 |
| Frazier Life Science | U-Tender | 17,199 | $1.95 | 2025-09-17 |
| HERSHBERG ROBERT | U-Tender | 1,101,498 | $1.95 | 2025-09-17 |
| Cocero Nanette | U-Tender | 17,199 | $1.95 | 2025-09-17 |
| HILLEMAN JERYL L | U-Tender | 59,224 | $1.95 | 2025-09-17 |